Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

EDG-15400

Small molecule · developed by Edgewise Therapeutics

Phase 2 Most advanced trial

EWTX Developer

2 Registered trials

What is EDG-15400?

EDG-15400 is an oral small molecule administered once daily. It is being studied in heart failure with preserved ejection fraction and in healthy adults.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Small molecule
Therapy area: Cardiovascular
Developer: Edgewise Therapeutics, Inc. (EWTX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07795814	Phase 2	Heart Failure With Preserved Ejection Fraction	Recruiting	EWTX
NCT07177066	Phase 1	Healthy Adults	Completed	EWTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Heart Failure With Preserved Ejection FractionHealthy Adults

More from Edgewise Therapeutics

EDG-7500 Phase 2 Sevasemten Phase 2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the EWTX page.

Follow EWTX, the company behind EDG-15400

See EWTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

EWTX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z